Future lease payments under the non-cancelable operating leases as of September 30, 2023 are as follows:

As described further in Note 6, in August 2023, the Company entered into new work orders under the WuXi Agreement for WuXi to serve as one of the Company’s cell processing manufacturing partners for the planned global clinical development of CABA-201. Under the August 2023 work orders, WuXi will convert the Company’s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company’s CABA-201 and MuSK-CAART programs, for an initial term of 18 months. The Company would incur a $1,080 termination fee if it terminates both the CABA-201 and MuSK-CAART work orders for any reason. As of September 30, 2023, the

Company has concluded that this lease has not yet commenced and no right of use asset or lease liability has been included in the accompanying balance sheets.